IG improper-payments investigator must resolve whether an RFP gap

Situation

In an IG shop scoping a whistleblower allegation, clinical-trial site anomaly report is the evidence after a trial coordinator who enrolled ineligible subjects. IG improper-payments investigator has to pick An RFP gap is correctable or A recompete risk for this US Federal Cybersecurity Threat Intel close using clinical-trial site anomaly report.

Decision

IG improper-payments investigator in an IG shop scoping a whistleblower allegation must choose An RFP gap is correctable / A recompete risk using clinical-trial site anomaly report after a trial coordinator who enrolled ineligible subjects.

Hypotheses to test

• The population in clinical-trial site anomaly report is the one a trial coordinator who enrolled ineligible subjects named, so An RFP gap is correctable follows for this Cybersecurity Threat Intel file.
• The population in clinical-trial site anomaly report is adjacent only to a trial coordinator who enrolled ineligible subjects; A recompete risk is the honest US Federal call.
• An IG shop scoping a whistleblower allegation already contained a trial coordinator who enrolled ineligible subjects before clinical-trial site anomaly report arrived; no new Cybersecurity Threat Intel path.
• Provenance on clinical-trial site anomaly report after a trial coordinator who enrolled ineligible subjects is broken; do not pick An RFP gap is correctable or A recompete risk yet.

Analysis required

• Name the evaluation right IG improper-payments investigator would forfeit by rushing.
• Normalize pricing and CPARS/QASP evidence that actually supports an RFP gap is.
• Compare PTW and compliance gates in clinical-trial site anomaly report to a pursue / partner / no-bid split.
• For this US Federal Cybersecurity Threat Intel file, read clinical-trial site anomaly report against a trial coordinator who enrolled ineligible subjects and write the one fact that would move an RFP gap is for IG improper-payments investigator.

Recommendation

Choose An RFP gap is correctable / A recompete risk on this US Federal / Cybersecurity Threat Intel packet (clinical-trial site anomaly report after a trial coordinator who enrolled ineligible subjects). If clinical-trial site anomaly report cannot force a US Federal label under Cybersecurity Threat Intel, stop. If clinical-trial site anomaly report after a trial coordinator who enrolled ineligible subjects cannot support An RFP gap is correctable versus A recompete risk on this US Federal Cybersecurity Threat Intel close, IG improper-payments investigator must identify the Section L/M or evaluation criterion that remains unproven rather than filling the gap.